Montreal Clinical Research Institute (IRCM), Montréal, Québec, Canada.
Department of Nutrition, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Diabetes Obes Metab. 2024 Oct;26(10):4744-4752. doi: 10.1111/dom.15844. Epub 2024 Aug 9.
The relative contributions of insulin secretory defects and possible additional contribution of insulin resistance for the development of cystic fibrosis (CF)-related diabetes (CFRD) are poorly understood. We aimed to (a) determine which indices of insulin resistance predict progression to CFRD, and (b) to model the relative contributions of insulin secretory function and insulin resistance to predict the risk of CFRD.
Three hundred and three individuals living with CF underwent a 2-h oral glucose tolerance test with blood sampling every 30 min at 12-24-month intervals until they developed CFRD or until the end of follow-up (up to 15 years). Indices of insulin resistance (e.g. Stumvoll) and insulin secretion were calculated from oral glucose tolerance test glucose and insulin measurements. CFRD-free survival was assessed by survival analysis.
Estimated insulin resistance showed associations with glucose homeostasis and risk of progression to CFRD. The CFRD-free survival was significantly different between quartiles of insulin resistance (p < 0.0001). When patients were subdivided according to both insulin resistance and insulin secretion (insulinogenic index), CFRD-free survival was significantly lower in those with combined lowest insulin secretion and highest insulin resistance (Stumvoll) indices (hazard ratio: 11.2; p < 0.0001). There was no significant difference when the same analysis was performed for the nine other indices.
Insulin resistance is correlated with glucose homeostasis and the risk of progression to CFRD. Patients combining low insulin secretion and high insulin resistance had the greatest odds of developing CFRD over a 15-year period.
胰岛素分泌缺陷以及胰岛素抵抗可能的附加作用对囊性纤维化(CF)相关糖尿病(CFRD)的发展的相对贡献仍不清楚。我们旨在:(a)确定哪些胰岛素抵抗指数可预测 CFRD 的进展,以及(b)建立胰岛素分泌功能和胰岛素抵抗的相对作用模型,以预测 CFRD 的发病风险。
303 名 CF 患者每 12-24 个月进行一次 2 小时口服葡萄糖耐量试验(OGTT),并在试验过程中每隔 30 分钟采集一次血样,直至发生 CFRD 或随访结束(最长 15 年)。从 OGTT 葡萄糖和胰岛素测量中计算胰岛素抵抗(如 Stumvoll)和胰岛素分泌的指数。通过生存分析评估 CFRD 无进展生存率。
估计的胰岛素抵抗与葡萄糖稳态和进展为 CFRD 的风险相关。胰岛素抵抗的四分位区间之间的 CFRD 无进展生存率有显著差异(p<0.0001)。当根据胰岛素抵抗和胰岛素分泌(胰岛素生成指数)将患者细分时,胰岛素抵抗和胰岛素分泌均处于最低水平的患者(Stumvoll)的 CFRD 无进展生存率显著降低(危险比:11.2;p<0.0001)。当对其他 9 个指数进行相同的分析时,无显著差异。
胰岛素抵抗与葡萄糖稳态和进展为 CFRD 的风险相关。在 15 年的时间里,胰岛素分泌和胰岛素抵抗均处于最低水平的患者发生 CFRD 的几率最高。